SCHEMBL2683121

SCHEMBL2683121

CCOC(=O)Cc1cc(C(=O)c2ccc3cc(-c4ccccc4)[nH]c3c2)sc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
TUBB4A P04350 2/20 0.42
TUBB P07437 2/20 0.42
TUBA3C P0DPH7 2/20 0.42
TUBA1B P68363 2/20 0.42
TUBA4A P68366 2/20 0.42
TUBB4B P68371 2/20 0.42
TUBB3 Q13509 2/20 0.42
TUBB2A Q13885 2/20 0.42
TUBB8 Q3ZCM7 2/20 0.42
TUBA3E Q6PEY2 2/20 0.42
TUBA1A Q71U36 2/20 0.42
TUBA1C Q9BQE3 2/20 0.42
TUBB6 Q9BUF5 2/20 0.42
TUBB2B Q9BVA1 2/20 0.42
TUBB1 Q9H4B7 2/20 0.42
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2682508 0.87 CASP3 (0.54) CASP3SENP8SENP7SENP6ALDH1A1
SCHEMBL3056696 0.76 CASP3 (0.55) CASP3SENP8SENP7SENP6ALDH1A1
SCHEMBL3047750 0.76 CASP3 (0.52) CASP3SENP8SENP7SENP6LMNA
SCHEMBL5026628 0.76 CASP3 (0.52) CASP3SENP8SENP7SENP6LMNA
SCHEMBL3058848 0.75 CASP3 (0.51) CASP3SENP8SENP7SENP6ALDH1A1
SCHEMBL2683137 0.69 PARP1 (0.42) LMNAKDM4EALDH1A1HPGDMAPT
SCHEMBL29941485 0.67 CASP3 (1.00) CASP3SENP8SENP7SENP6LMNA
SCHEMBL3704691 0.67 CASP3 (1.00) CASP3SENP8SENP7SENP6LMNA
SCHEMBL4880986 0.67 CASP3 (0.71) CASP3SENP8SENP7SENP6TUBB4A
SCHEMBL1260807 0.66 TUBB4A (0.72) CASP3SENP8SENP7SENP6TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404728-B2 Small-molecule botulinum toxin inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2013-03-26 US disclosed
US-20120114696-A1 SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS US ARMY, SECRETARY OF THE ARMY 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120114696-A1 SMALL-MOLECULE BOTULINUM TOXIN INHIBITORS BTD, BCHE, ACHE CASP3 2001/4885SENP8 1042/4885SENP7 1546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.